Linked Life Data

19392858

Source:http://linkedlifedata.com/resource/pubmed/id/19392858

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-7-23
pubmed:abstractText
Benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory bowel disease (IBD) patients have not been adequately evaluated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1365-2036
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
210-26
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
pubmed:affiliation
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. grl@uphs.upenn.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't